Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. Oncology Companion Diagnostic Market, by Region, 2018-2027 (USD Billion)
1.2.2. Oncology Companion Diagnostic Market, by Product & Service, 2018-2027 (USD Billion)
1.2.3. Oncology Companion Diagnostic Market, by Technology, 2018-2027 (USD Billion)
1.2.4. Oncology Companion Diagnostic Market, by Disease Type, 2018-2027 (USD Billion)
1.2.5. Oncology Companion Diagnostic Market, by End Use, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Oncology Companion Diagnostic Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Oncology Companion Diagnostic Market Dynamics
3.1. Oncology Companion Diagnostic Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Oncology Companion Diagnostic Market: Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Oncology Companion Diagnostic Market, by Product & Service
5.1. Market Snapshot
5.2. Global Oncology Companion Diagnostic Market by Product & Service, Performance - Potential Analysis
5.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Product & Service 2017-2027 (USD Billion)
5.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
5.4.1. Product
5.4.2. Services
Chapter 6. Global Oncology Companion Diagnostic Market, by Technology
6.1. Market Snapshot
6.2. Global Oncology Companion Diagnostic Market by Technology, Performance - Potential Analysis
6.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Technology 2017-2027 (USD Billion)
6.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
6.4.1. Polymerase Chain Reaction (PCR)
6.4.2. Next-Generation Sequencing (NGS)
6.4.3. Immunohistochemistry (IHC)
6.4.4. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
6.4.5. Others
Chapter 7. Global Oncology Companion Diagnostic Market, by Disease Type
7.1. Market Snapshot
7.2. Global Oncology Companion Diagnostic Market by Disease Type, Performance - Potential Analysis
7.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Disease Type 2017-2027 (USD Billion)
7.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
7.4.1. Breast Cancer
7.4.2. Non-Small Cell Lung Cancer
7.4.3. Colorectal Cancer
7.4.4. Leukemia
7.4.5. Melanoma
7.4.6. Prostate Cancer
7.4.7. Others
Chapter 8. Global Oncology Companion Diagnostic Market, by End Use
8.1. Market Snapshot
8.2. Global Oncology Companion Diagnostic Market by End Use, Performance - Potential Analysis
8.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by End Use 2017-2027 (USD Billion)
8.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
8.4.1. Hospital
8.4.2. Pathology/Diagnostic Laboratory
8.4.3. Academic Medical Center
Chapter 9. Global Oncology Companion Diagnostic Market, Regional Analysis
9.1. Oncology Companion Diagnostic Market, Regional Market Snapshot
9.2. North America Oncology Companion Diagnostic Market
9.2.1.1. U.S. Oncology Companion Diagnostic Market
9.2.1.2. Product & Service breakdown estimates & forecasts, 2017-2027
9.2.1.3. Technology breakdown estimates & forecasts, 2017-2027
9.2.1.4. Disease Type breakdown estimates & forecasts, 2017-2027
9.2.1.5. End Use breakdown estimates & forecasts, 2017-2027
9.2.2. Canada Oncology Companion Diagnostic Market
9.3. Europe Oncology Companion Diagnostic Market Snapshot
9.3.1. U.K. Oncology Companion Diagnostic Market
9.3.2. Germany Oncology Companion Diagnostic Market
9.3.3. France Oncology Companion Diagnostic Market
9.3.4. Spain Oncology Companion Diagnostic Market
9.3.5. Italy Oncology Companion Diagnostic Market
9.3.6. Rest of Europe Oncology Companion Diagnostic Market
9.4. Asia-Pacific Oncology Companion Diagnostic Market Snapshot
9.4.1. China Oncology Companion Diagnostic Market
9.4.2. India Oncology Companion Diagnostic Market
9.4.3. Japan Oncology Companion Diagnostic Market
9.4.4. Australia Oncology Companion Diagnostic Market
9.4.5. South Korea Oncology Companion Diagnostic Market
9.4.6. Rest of Asia Pacific Oncology Companion Diagnostic Market
9.5. Latin America Oncology Companion Diagnostic Market Snapshot
9.5.1. Brazil Oncology Companion Diagnostic Market
9.5.2. Mexico Oncology Companion Diagnostic Market
9.6. Rest of The World Oncology Companion Diagnostic Market

Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Agilent Technologies, Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Illumina, Inc.
10.2.3. QIAGEN N.V.
10.2.4. Thermo Fisher Scientific, Inc.
10.2.5. F. Hoffmann-La Roche Ltd.
10.2.6. ARUP Laboratories
10.2.7. Abbott
10.2.8. Myriad Genetics, Inc.
10.2.9. bioMerieux SA
10.2.10. Invivoscribe, Inc.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption